330 patients, cabozantinib 140 mg (n = 219) or placebo (n = 111)
need 217 events to do OS analysis,
projecting that later in this year or in 2014.
the interim analysis recall we had only 44% of the events that are required for the final analysis(that was about 95 events at interim analysis)
The 1-year PFS rate was 47.3% for the cabozantinib arms versus 7.2% with placebo. Data for overall survival (OS), are not yet mature
So, it takes about 1.5 years for another 122 events to happen. It seems that after some point of time, the event rate drop dramatically no matter if progressed or not, on cabo or not. Is my understanding correct?